February 24, 2017 08:22 AM EST

Struggling Ohr shutters lab after halting enrollment for PhIII wet AMD study

Arsalan Arif

Founder

A few days ago the struggling microcap biotech Ohr Pharmaceutical $OHRP told investors it would “pause” enrollment in their Phase III study of squalimine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Struggling Ohr shutters lab after halting enrollment for PhIII wet AMD study

Arsalan Arif

Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Two GSK trials with long-acting drug in chronic rhinosinusitis hit primary endpoints

Pfizer details results from failed Phase 3 trial of Duchenne muscular dystrophy gene therapy

Novo Nordisk files 18 lawsuits against GLP-1 compounders in 44 days

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Exclusive: British startup raises $16M to find genes that rewind the epigenetic clock

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Strug­gling Ohr shut­ters lab af­ter halt­ing en­roll­ment for PhI­II wet AMD study

Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Struggling Ohr shutters lab after halting enrollment for PhIII wet AMD study